SCHEMBL11989337

SCHEMBL11989337

CCC(=O)c1ccc(N)cc1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 1/20 0.47
PDE10A Q9Y233 1/20 0.45
ALDH1A1 P00352 3/20 0.45
CYP3A4 P08684 2/20 0.43
CYP1A2 P05177 2/20 0.43
LMNA P02545 2/20 0.43
MAOA P21397 1/20 0.43
ADRB2 P07550 1/20 0.43
ADRB1 P08588 1/20 0.43
ADRB3 P13945 1/20 0.43
MAPT P10636 3/20 0.41
GAA P10253 2/20 0.41
KDM4E B2RXH2 2/20 0.41
ESR2 Q92731 1/20 0.41
PTPN1 P18031 1/20 0.41
CASP1 P29466 2/20 0.41
TSHR P16473 1/20 0.41
POLB P06746 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CRBN Q96SW2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10807463 0.85 ALDH1A1 (0.46) PDE10AALDH1A1CYP3A4CYP1A2LMNA
SCHEMBL11989292 0.85 CASP1 (0.45) HSP90AB1PDE10AALDH1A1CYP3A4CYP1A2
SCHEMBL9559750 0.82 HSP90AB1 (0.48) HSP90AB1ALDH1A1CYP3A4CYP1A2LMNA
SCHEMBL21089962 0.81 HSP90AB1 (0.67) HSP90AB1ALDH1A1CYP3A4LMNAMAPT
SCHEMBL581464 0.80 HSD11B1 (0.54) HSP90AB1ALDH1A1HTTNPC1
SCHEMBL7186665 0.79 ALDH1A1 (0.52) PDE10AALDH1A1CYP3A4CYP1A2LMNA
SCHEMBL10031578 0.79 CHRM2 (0.52) HSP90AB1ALDH1A1CYP3A4MAOAMAPT
SCHEMBL27955097 0.79 HSP90AB1 (0.46) HSP90AB1ALDH1A1CYP3A4CYP1A2LMNA
SCHEMBL14047784 0.79 HSP90AB1 (0.46) HSP90AB1ALDH1A1CYP3A4MAOAMAPT
SCHEMBL9041388 0.78 MAPT (0.57) HSP90AB1ALDH1A1CYP3A4MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43802-E1 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE LLC (US) 2012-11-13 US disclosed
US-RE43596-E1 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE LLC (US) 2012-08-21 US disclosed
US-RE42889-E1 α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE LLC (US) 2011-11-01 US disclosed
US-7829564-B2 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE LLC (US) 2010-11-09 US disclosed
US-7531538-B2 α- and β-Amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors G.D. SEARLE LLC (US) 2009-05-12 US disclosed
US-20090023664-A1 ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE LLC (US) 2009-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023664-A1 ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS DNPEP, ASPH, PREP HSP90AB1 264/4885PDE10A 4425/4885ALDH1A1 1555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.